Do we need a different set of response assessment criteria for tumor immunotherapy?

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 15 ·No. 23 ·2009-12-01 ·Pages 7116-8

Ribas A, Chmielowski B, Glaspy JA

Abstract

Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.

MeSH Terms

Antibodies, Monoclonal/pharmacology Clinical Trials, Phase II as Topic Humans Immunotherapy/methods Inflammation/pathology Ipilimumab Medical Oncology/standards Models, Biological Neoplasm Metastasis Neoplasms/immunology,therapy Randomized Controlled Trials as Topic Treatment Outcome

Chemicals

Antibodies, Monoclonal Ipilimumab

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Ribas Antoni

Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California 90095-1782, USA. aribas@mednet.ucla.edu

Chmielowski Bartosz

Glaspy John A

Article Info

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Abbr.

Clin Cancer Res

ISSN

1557-3265

DOI

10.1158/1078-0432.CCR-09-2376

aribas@mednet.ucla.edu

Published

2009-12-01

Epub

2009-00-24

Pages

7116-8

Language

English

Region

United States

NLM ID

9502500

Subset

Corrections

CommentOn

PMID: 19934295

External Links

PubMed source DOI: 10.1158/1078-0432.CCR-09-2376 View journal details

Analysis Services

Do we need a different set of response assessment criteria for tumor immunotherapy?

Contact

WeChat Official Account